Breaking Finance News

Zacks Investment Research disclosed Abbott Laboratories (NYSE:ABT), boosting its price target to $55.00 earlier today

Stating a potential upside of 0.13%, Zacks Investment Research raised the target price of Abbott Laboratories (NYSE:ABT) to $55.00

Just yesterday Abbott Laboratories (NYSE:ABT) traded 0.14% higher at $48.77. Abbott Laboratories’s 50-day moving average is $50.01 and its 200-day moving average is $46.93. The last stock price is up 10.29% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 6,699,659 shares of ABT traded hands, up from an average trading volume of 5,431,240

Recent Performance Chart

Abbott Laboratories (NYSE:ABT)

Abbott Laboratories has 52 week low of $37.38 and a 52 week high of $52.60 with a PE ratio of 72.49 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 15 brokerages have issued a ratings update on the company. The average stock price target is $46.73 with 6 brokerages rating the stock a strong buy, 8 brokerages rating the stock a buy, 6 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Abbott Laboratories (NYSE:ABT)

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.